Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Akoya Biosciences, Inc.

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. 

Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels, PhenoCycler®, PhenoImager® Fusion, and PhenoImager HT Instruments.

View our open job descriptions: www.akoyabio.com/careers

Follow us on Twitter: www.twitter.com/AkoyaBio   

Subscribe to our YouTube channel: www.youtube.com/c/AkoyaBiosciences 

Innovatus Capital Partners

Telegraph Hill Partners

Piper Jaffray Merchant Banking

Thomas Schnettler

We are excited to welcome Crown Bioscience as an Akoya-qualified service provider! Headquartered in San Diego, CA, Crown Bioscience aims to support drug discovery through translational research across oncology and immuno-oncology.

By joining our Contract Research Organization Network, Crown Bioscience will utilize Akoya's Phenomager HT platform to offer advanced multispectral imaging technology, easily integrated into high-throughput workflows to accommodate projects regardless of scale.

Explore Crown Bioscience's digital pathology technologies: https://bit.ly/3T0ALxY

#oncology #immunooncology #drugdiscovery #phenoimager #crownbioscience

This groundbreaking study, published in Nature using our PhenoImager HT platform, offers a fresh perspective on the pathology and heterogeneity of rheumatoid arthritis. The findings hold promise for developing innovative targeted treatments for patients with this condition. 

🙌 Kudos to the authors for their valuable contribution to understanding this debilitating, autoimmune disease without a cure!

#FridayRead #PhenoImager #AkoyaInAction #SpatialBiology #RheumatoidArthritis

Join us at the Cancer Neuroscience Symposium at the MD Anderson Cancer Center in Houston, Texas!

The Akoya team will be there today and tomorrow and will be happy to discuss how our spatial biology solutions are making a difference in neuroscience and cancer research. 

Not attending? Explore our solutions on our website: https://bit.ly/47GvLFB

#SpatialBiology #Neuroscience #MDAnderson #CancerResearch #Immunology

Dr. Tom Lund and his team at the Integrated Pathology Unit (IPU) in London have consistently used our instruments, with the PhenoImager HT serving as a central resource in their laboratory.

The IPU, a collaborative effort between The Institute of Cancer Research and the Royal Marsden Hospital, is crucial in bridging clinical, translational, and basic research. Dr. Lund attributes the IPU's flexibility to their tissue-agnostic Akoya technology, which requires minimal tissue-specific optimization, allowing seamless adaptation to diverse research requirements.

We are thankful for Dr. Lund's ongoing support of our technology. We are excited to witness his lab's advancements in further understanding and treating cancer through multiplex immunofluorescence.

#spatialbiology #digitalpathology #multiplex #phenoimager SelectScience®

📢 Tomorrow is part 1 of a 2-part webinar series on fusing single-cell genomics and spatial proteomics with MaxFuse!

Hear Garry Nolan, Ph.D., discuss MaxFuse, a new AI algorithm that provides reliable, fast, and cost-effective integration of spatial proteomic data with single-cell transcriptomic and epigenomic datasets. 

This webinar will be offered at two different times on Feb 28th; attendees can join at 3 AM PT/6 AM ET/12 PM CET or 9 AM PT/12 PM ET/6 PM CET. 

Hope to see you there!

#spatialbiology #spatialproteomics #maxfuse #singlecell #genomics Genetic Engineering & Biotechnology News 

msh id	COM:AKOYABIO
symbol	AKYA
name	Akoya Biosciences, Inc.
homepage url	https://www.akoyabio.com
country	US
sector	Healthcare
industry	Medical - Instruments & Supplies
market	STOCKS
employee count	330
crunchbase url	-
linkedin url	-
founders	-

market cap	102.72M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	14.4K
monthly webtraffic growth	0.17
growth score 14	13.91
growth score 28	48.33
growth score 90	43.23
growth score 365	45.19

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.08
growth cost of revenue	0.54
growth depreciation and amortization	0.29
growth ebitda	0.21
growth ebitda ratio	0.38
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	0.11
growth gross profit ratio	-0.14

COM:AKOYABIO

Akoya Biosciences, Inc.

Last Close

2.16

21/11 21:00

Market Cap

102.72M

Beta: -

Volume Today

135.36K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	152.67M
cost of revenue	152.67M
depreciation and amortization	8.89M
ebitda	-47.14M
ebitda ratio	-0.49
eps	-1.43
eps diluted	-1.43
operating expenses	104.27M
operating income	-56.03M
operating income ratio	-0.58

accounts receivables	-7.27M
capital expenditure	-3.65M
cash at beginning of period	74.23M
cash at end of period	83.13M
inventory	17.88M
working capital ttm	81.43M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-